导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -17.14% | 4213/4773 |
| 近一周 | -4.09% | 5001/5465 |
| 近一月 | -3.50% | 2567/5421 |
| 近一季 | 1.09% | 773/5231 |
| 近半年 | -16.93% | 4210/4920 |
| 近一年 | -24.68% | 4087/4394 |
| 近两年 | -2.16% | 2906/2954 |
| 近三年 | -28.41% | 2197/2253 |
| 成立以来 | 112.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.69% 3914/4961 |
-16.44% 4734/5312 |
- - |
- - |
| 2025 | -2.84% 3343/4813 |
-0.42% 2243/3635 |
-2.23% 3328/4076 |
6.03% 3556/4524 |
-5.88% 3639/4813 |
| 2024 | -3.90% 2224/3463 |
1.01% 907/2808 |
-9.16% 2327/3014 |
14.34% 2000/3129 |
-8.40% 2859/3463 |
| 2023 | -16.99% 1709/2656 |
2.20% 1410/2280 |
-12.60% 2186/2385 |
-1.43% 518/2515 |
-5.71% 1471/2655 |
| 2022 | -12.89% 305/2207 |
-16.05% 1095/1919 |
14.24% 204/2016 |
-9.18% 252/2113 |
0.02% 1547/2208 |
| 2021 | -6.27% 1002/1822 |
-6.25% 990/1255 |
3.84% 950/1330 |
-10.19% 1214/1466 |
7.21% 192/1822 |
| 2020 | 69.37% 75/1250 |
2.02% 138/1028 |
19.69% 293/1067 |
16.97% 124/1164 |
18.58% 88/1184 |
| 2019 | 62.32% 45/1092 |
40.15% 55/754 |
10.33% 7/804 |
1.67% 376/850 |
3.25% 841/918 |
| 2018 | -20.61% 194/834 |
- - |
- - |
- - |
-14.38% 582/691 |
| 2017 | 55.65% 8/714 |
- - |
- - |
- - |
- - |
| 2016 | 1.91% 89/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇添富中证主要消费ETF联接A VS. 长安沪深300非周期A(740101) |